A recent study conducted by the Karolinska Institutet has found that people with type 2 diabetes who are treated with glucagon-like peptide-1 agonists, such as Ozempic, have a reduced risk of developing dementia. The findings, published in the journal eClinicalMedicine, suggest that this class of medication could have a protective effect on cognitive health for diabetic patients. Type 2 diabetes is a chronic condition characterized by high blood sugar levels due to insulin resistance or inadequate insulin production. Individuals with this condition are at a significantly higher risk of develop…